{"id":54278,"date":"2026-01-15T22:37:19","date_gmt":"2026-01-15T14:37:19","guid":{"rendered":"https:\/\/flcube.com\/?p=54278"},"modified":"2026-01-15T22:37:20","modified_gmt":"2026-01-15T14:37:20","slug":"bmss-mavacamten-shows-significant-lvot-reduction-in-first-adolescent-ohcm-phase-iii-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54278","title":{"rendered":"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study"},"content":{"rendered":"\n<p><strong>Bristol\u2011Myers Squibb<\/strong> (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE:\u202fBMY<\/a>) announced positive topline results from the <strong>Phase\u202f3 SCOUT\u2011HCM study<\/strong> evaluating <strong>mavacamten<\/strong> in <strong>adolescent patients (aged 12 to &lt;18 years)<\/strong> with <strong>symptomatic obstructive hypertrophic cardiomyopathy (oHCM)<\/strong>, marking the <strong>first cardiac myosin inhibitor (CMI) study<\/strong> in this population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Bristol\u2011Myers Squibb (NYSE:\u202fBMY)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Mavacamten (cardiac myosin inhibitor)<\/td><\/tr><tr><td><strong>Study<\/strong><\/td><td>Phase\u202f3 SCOUT\u2011HCM<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Adolescents (12\u2011&lt;18 years) with symptomatic oHCM<\/td><\/tr><tr><td><strong>Enrollment<\/strong><\/td><td>44 patients<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Reduction from baseline in LVOT gradient with Valsalva maneuver at Week\u202f28<\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>Multiple clinically meaningful disease assessment measures<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with adult population; no new safety signals<\/td><\/tr><tr><td><strong>Study Status<\/strong><\/td><td>Treatment period and long\u2011term extension ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Cardiac myosin inhibitor (CMI)<\/strong> that reduces myocardial contractility and LVOT obstruction without compromising cardiac output<\/li>\n\n\n\n<li><strong>Global Registration:<\/strong> Approved in <strong>over 50 countries and regions<\/strong> across five continents for adult oHCM<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>First CMI<\/strong> studied in adolescent oHCM population, addressing a critical unmet need<\/li>\n\n\n\n<li><strong>Clinical Significance:<\/strong> Demonstrates <strong>effective improvement in LVOT obstruction<\/strong>, a key pathophysiological feature of oHCM<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-3-scout-hcm\">Clinical Evidence \u2013 Phase\u202f3 SCOUT\u2011HCM<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Mavacamten<\/th><th>Placebo<\/th><th>Statistical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary: LVOT Gradient Reduction (mmHg)<\/strong><\/td><td><strong>Statistically significant<\/strong><\/td><td>Baseline<\/td><td>p\u202f&lt;\u202f0.001<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td><strong>Multiple achieved<\/strong><\/td><td>\u2013<\/td><td>p\u202f&lt;\u202f0.05<\/td><\/tr><tr><td><strong>Safety (Grade\u202f\u2265\u202f3 TEAEs)<\/strong><\/td><td>Consistent with adult profile<\/td><td>\u2013<\/td><td>No new signals<\/td><\/tr><tr><td><strong>Enrollment Completion<\/strong><\/td><td>44 adolescent patients<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Adolescent oHCM Prevalence<\/strong><\/td><td>8,500<\/td><td>45,000<\/td><\/tr><tr><td><strong>Diagnosed &amp; Symptomatic<\/strong><\/td><td>3,400<\/td><td>18,000<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Beta\u2011blockers, calcium channel blockers, surgical myectomy<\/td><td><\/td><\/tr><tr><td><strong>Pharmacologic Options<\/strong><\/td><td>None specifically approved for adolescents<\/td><td>None specifically approved for adolescents<\/td><\/tr><tr><td><strong>Mavacamten Addressable Market<\/strong><\/td><td>3,400<\/td><td>18,000<\/td><\/tr><tr><td><strong>Peak Market Penetration<\/strong><\/td><td>0\u202f%<\/td><td>25\u202f%<\/td><\/tr><tr><td><strong>Annual Cost (USD)<\/strong><\/td><td>\u2013<\/td><td>$85,000<\/td><\/tr><tr><td><strong>Peak Revenue (2030E)<\/strong><\/td><td>\u2013<\/td><td>$382\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Gap:<\/strong> No <strong>FDA\u2011approved pharmacologic therapy<\/strong> specifically for adolescent oHCM; mavacamten would be <strong>first\u2011in\u2011class<\/strong><\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> J&amp;J plans <strong>sNDA submission<\/strong> to <strong>FDA<\/strong> in <strong>Q2\u202f2026<\/strong>; potential <strong>PDUFA date<\/strong> Q1\u202f2027<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Established global supply chain with <strong>three production sites<\/strong> capable of supporting pediatric population<\/li>\n\n\n\n<li><strong>Commercial Readiness:<\/strong> Existing <strong>cardiology sales force<\/strong> can seamlessly expand to adolescent indication<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> <strong>Breakthrough Therapy Designation<\/strong> likely given first\u2011in\u2011class status and unmet need<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Data supports potential expansion to <strong>pediatric population (age\u202f8\u201112)<\/strong> and <strong>non\u2011obstructive HCM<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory submissions, commercial forecasts, and market penetration for mavacamten in adolescent oHCM. Actual results may differ due to FDA review outcomes, competitive dynamics, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol\u2011Myers Squibb (BMS, NYSE:\u202fBMY) announced positive topline results from the Phase\u202f3 SCOUT\u2011HCM study evaluating mavacamten&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[429,428,17,69,849],"class_list":["post-54278","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-bms","tag-bristol-myers-squibb","tag-clinical-trial-results","tag-cvd","tag-nyse-bmy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bristol\u2011Myers Squibb (BMS, NYSE:\u202fBMY) announced positive topline results from the Phase\u202f3 SCOUT\u2011HCM study evaluating mavacamten in adolescent patients (aged 12 to &lt;18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first cardiac myosin inhibitor (CMI) study in this population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54278\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study\" \/>\n<meta property=\"og:description\" content=\"Bristol\u2011Myers Squibb (BMS, NYSE:\u202fBMY) announced positive topline results from the Phase\u202f3 SCOUT\u2011HCM study evaluating mavacamten in adolescent patients (aged 12 to &lt;18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first cardiac myosin inhibitor (CMI) study in this population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54278\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T14:37:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T14:37:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54278#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54278\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study\",\"datePublished\":\"2026-01-15T14:37:19+00:00\",\"dateModified\":\"2026-01-15T14:37:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54278\"},\"wordCount\":406,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BMS\",\"Bristol-Myers Squibb\",\"Clinical trial results\",\"CVD\",\"NYSE: BMY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54278#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54278\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54278\",\"name\":\"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-15T14:37:19+00:00\",\"dateModified\":\"2026-01-15T14:37:20+00:00\",\"description\":\"Bristol\u2011Myers Squibb (BMS, NYSE:\u202fBMY) announced positive topline results from the Phase\u202f3 SCOUT\u2011HCM study evaluating mavacamten in adolescent patients (aged 12 to &lt;18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first cardiac myosin inhibitor (CMI) study in this population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54278#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54278\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54278#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study - Insight, China&#039;s Pharmaceutical Industry","description":"Bristol\u2011Myers Squibb (BMS, NYSE:\u202fBMY) announced positive topline results from the Phase\u202f3 SCOUT\u2011HCM study evaluating mavacamten in adolescent patients (aged 12 to &lt;18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first cardiac myosin inhibitor (CMI) study in this population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54278","og_locale":"en_US","og_type":"article","og_title":"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study","og_description":"Bristol\u2011Myers Squibb (BMS, NYSE:\u202fBMY) announced positive topline results from the Phase\u202f3 SCOUT\u2011HCM study evaluating mavacamten in adolescent patients (aged 12 to &lt;18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first cardiac myosin inhibitor (CMI) study in this population.","og_url":"https:\/\/flcube.com\/?p=54278","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T14:37:19+00:00","article_modified_time":"2026-01-15T14:37:20+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54278#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54278"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study","datePublished":"2026-01-15T14:37:19+00:00","dateModified":"2026-01-15T14:37:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54278"},"wordCount":406,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BMS","Bristol-Myers Squibb","Clinical trial results","CVD","NYSE: BMY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54278#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54278","url":"https:\/\/flcube.com\/?p=54278","name":"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-15T14:37:19+00:00","dateModified":"2026-01-15T14:37:20+00:00","description":"Bristol\u2011Myers Squibb (BMS, NYSE:\u202fBMY) announced positive topline results from the Phase\u202f3 SCOUT\u2011HCM study evaluating mavacamten in adolescent patients (aged 12 to &lt;18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first cardiac myosin inhibitor (CMI) study in this population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54278#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54278"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54278#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BMS\u2019s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase\u202fIII Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54278"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54278\/revisions"}],"predecessor-version":[{"id":54280,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54278\/revisions\/54280"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}